Consequently, therapeutic strategies that target USP38 or its downstream effectors—such as small-molecule inhibitors or gene-silencing approaches—may provide novel avenues for the precision treatment of CKD-associated AF, with significant translational potential. The gene discussed is USP38; the disease is chronic kidney disease.